Based on these results, Roche conducted a phase III trial (SKYSCRAPER-01, NCT04294810) to evaluate the superiority of tiragolumab plus atezolizumab over atezolizumab in treatment-naïve patients with advanced NSCLC expressing PD-L1; however, the recently released results of the interim analysis showed that the trial did not meet the PFS; hence, the study will continue investigating the OS until the next planned analysis (99). The gene discussed is CD274; the disease is non-small cell lung carcinoma.